Patient Information Document
NO0121PI-2 — 2025-07
EN

STERITALC® PF3 / PF3 Supplement
STERITALC® F2/F4

Sterile talc

MR CE 0297

NOVATECH SA

Société anonyme au capital de
160.000€
398 941 260 RCS Marseille
TVA CEE FR59398941260
Certifiée selon EN ISO 13485

Z.I.Athélia III - 1058, Voie Antiope
F-13705 La Ciotat CEDEX
France
Tel +33 (0) 442 98 15 60
Fax +33 (0) 442 98 15 63
info@novatech.fr
www.novatech.fr

9007199727210251 —10.09.2025 14:13

1 Dear Patient,

You have been given an implant of the type STERITALC. For your own safety, please read this Patient Information Document carefully and keep it somewhere safe. If you have any questions about your implant, please contact the physician who treats you.

2 About this Document

2.1 Symbols Glossary

Symbol	Description
	MR safe
	Catalog number
	Batch code
	Unique Device Identification (UDI)
	Manufacturer
	Patient name
	Date of implantation
	Name of the implanting healthcare institution / provider
	Patient information website

Table 1: Symbols Glossary

2.2 Safety Information Marking

⚠ WARNING

Non-compliance may result in serious injuries, serious deterioration of your general condition or your death.

2.3 Additional Information

Download link for the Patient Information Document:[1)]	www.novatech.fr/pi/no121pi
This patient information is based on the following instructions for use:	NO121-6 (STERITALC PF3) / NO123-6 (STERITALC F2/F4)
Disclaimer for the availability of the SSCP	As a general rule: The SSCP will only be made available after the product has been authorised in accordance with REGULATION (EU) 2017/745 (MDR). The implementation described here does not apply until the corresponding module of the Eudamed database comes into force. Until then, the SSCP is available at the following download link: www.novatech.fr/sscp/sscp121
Summary of Safety and Clinical Performance (SSCP): [1)]	https://ec.europa.eu/tools/eudamed To search for the product-specific SSCP, enter the basic UDI-DI of the product.
Basic UDI-DI (device identifier):	4063108STEBE

[1)] Updated on an ongoing basis.

The catalog number and batch code for your implant can be found on your implant card.

3 What you need to pay attention to

1. Always carry your implant card with you. Show your implant card and this Patient Information Document to your treating physician before undergoing diagnostic or therapeutic procedures.
2. Contact your doctor if you experience one or more of the following symptoms: Chest pain, fever, increasing difficulty breathing, cardiovascular problems

3. Stick to the appointments you make with your treating physician for follow-up examinations and observe their instructions for any necessary follow-up measures.

4 Product Description

4.1 General information

STERITALC is a sterile talc with a controlled particle size. STERITALC is either brought into the pleural cavity as a powder with the help of a flexible cannula and a powder blower or it is injected into the pleural cavity as a suspension.

4.2 Materials with Potential Patient Contact

Product (part)	Material	Contact person	Type of contact
Talc	100% Talc	Patient	With every use
Cannula (with STERITALC PF3 only)	100% Polyethylene	Patient	With every use (only during the procedure)

5 Intended use

5.1 Intended Purpose

STERITALC is an insoluble mineral powder, which is applied to the pleural cavity to cause permanent pleurodesis.
Application as slurry (STERITALC F2/F4) or poudrage (STERITALC PF3 / STERITALC F2/F4).
STERITALC PF3 SUPPLEMENT is intended to be used together with STERITALC PF3.

5.2 Patient Target Group

The product is suitable for use in the following patient groups:

- Adults
- Patients of all genders

5.3 Expected Lifetime

The concept of product life time is not applicable here: The product triggers an inflammatory reaction which leads to the desired effect. The further presence of the product is not relevant for the persistence of the desired effect. The persistence of the effect depends on factors not related to the product, such as progress of the disease.
The product is intended to remain in the body.

6 Possible Complications and Side Effects

The following product-related complications are known:

- Fever
- Infection (empyema, wound infection)
- Respiratory complications (respiratory insufficiency, pulmonary oedema, pneumonia, dyspnoea)
- Cardiovascular complications (dysrhythmia, myocardial infarction, hypotension, hypovolaemia)
- Complications related to the intervention (local bleeding, subcutaneous emphysema)

STERITALC has controlled particle size to minimize the risk of acute pneumonitis or ARDS (Acute Respiratory Distress Syndrome).

7 Combining with Other Procedures

The product is MRI safe.
Talc administration induces an inflammatory reaction. The inflammatory reaction activates the coagulation cascade, which leads to permanent pleurodesis. Do not give any anti-inflammatory medication before or after administering talc, because this may hinder the success of the treatment. Interferences with laboratory tests are possible.
False positive diagnoses are possible in Positron Emission Tomography (PET) and Computer Tomography (CT) exams (long lasting effect).

8 Other Residual Risks

Beyond the listed safety instructions, possible complications and side effects, no further significant residual risks are known.

9 Follow-up measures after removal of the product

The product is intended to remain in the body.